Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Where Will Recursion Pharmaceuticals Be in 5 Years?
10:00am, Sunday, 28'th Sep 2025
Recursion Pharmaceuticals (RXRX 1.84%), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at a
The Biotech Stock That's Too Risky for Most Investors
09:32am, Sunday, 28'th Sep 2025
The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is
10 Hidden-Gem AI Stocks to Buy Right Now
06:45am, Saturday, 27'th Sep 2025
While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
04:42am, Friday, 26'th Sep 2025
BigBear.ai (BBAI -6.00%) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days.
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
06:51pm, Monday, 22'nd Sep 2025
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
08:03pm, Monday, 08'th Sep 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Christopher Gibson - Co-Founder, CEO & Directo
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript
06:51pm, Wednesday, 03'rd Sep 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Cal
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
08:30am, Friday, 29'th Aug 2025
Prosper Junior Bakiny has positions in Nvidia and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia.
Recursion to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 27'th Aug 2025
Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in t
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
06:45am, Monday, 25'th Aug 2025
Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry. One way to do that is to buy shares of the leading companies in the field, such as Nvidia.
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
04:00am, Saturday, 23'rd Aug 2025
It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape ev
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
05:53pm, Friday, 22'nd Aug 2025
According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX 3.35%) stock was shedding more than 17% of its value week-to-date as of Thursday night.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
05:20am, Sunday, 10'th Aug 2025
Market darlings like Nvidia and Palantir Technologies are still solid investment prospects to be sure. After several years of big gains, however, these crowded trades are starting to show signs of age
Is Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?
11:31am, Friday, 08'th Aug 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the grea
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
12:51pm, Wednesday, 06'th Aug 2025
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
